<DOC>
	<DOCNO>NCT02039362</DOCNO>
	<brief_summary>The risk vertical HBV transmission relate HBV DNA level pregnant woman , around 30 % woman HBV DNA 1 , 000 000 I.U/mL despite serovaccination newborn . Using tenofovir DF last trimester pregnancy allow reduce risk , data Western country need .</brief_summary>
	<brief_title>Prevention Hepatitis B Virus Vertical Transmission Serovaccination Tenofovir During Pregnancy</brief_title>
	<detailed_description>The prevalence HBs Ag carriage pregnant woman varies France , accord native country , high rate originate sub-Saharan Africa Asia ( 5 8 % Parisian area ) . The level HBV DNA varies accord HBe status geographical origin , strongly predictive risk HBV mother-to-child transmission ( MTCT ) . The rate vertical transmission ( Yuan J et al . J Viral Hepatitis 2006 ) 0 % newborns mother HBV DNA le 100,000 copies/mL 40 % newborns mother HBV DNA 8 Log10 copies/mL , despite serovaccination birth , thus justify use tenofovir DF last trimester pregnancy highly viraemic pregnant woman , mentionned EASL 2012 Guidelines . Data need concern result strategy western country , justify prospective study .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>pregnant woman positive HBs Ag HBV DNA 100,000 I.U/mL HIV coinfection HDV coinfection requiring , accord physician 's decision , treatment prevent HBV MTC transmission</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>